Why Don't Americans Use Cost-Effectiveness Analysis?

American Journal of Managed Care

Volumn 10, Issue 5, 2004, Pages 308-312

  Neumann, Peter J ^a,b  

^a HARVARD CENTER FOR RISK ANALYSIS   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; DECISION MAKING; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH PROMOTION; PRIORITY JOURNAL; REVIEW; UNITED STATES;

COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; POLICY MAKING; UNITED STATES;

EID: 2442477423     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Elixhauser A, Luce BR, Taylor WR, Reblando J. Health care CBA/CEA: an update on the growth and composition of the literature. Med Care. 1993;31:JS1-JS138.
2. Elixhauser A, Halpern M, Schmier J, Luce BR. Health care CBA and CEA from 1991 to 1996: an updated bibliography. Med Care. 1998;36:MS1-MS9.
3. Neumann PJ, Stone PW, Chapman RH, Sandberg EA, Bell CM. The quality of reporting in published cost-utility analyses, 1976-1997. Ann Intern Med. 2000;132:964-972.
4. Hjelmgren J, Berggren F, Andersson F. Health economic guidelines-similarities, differences, and some implications. Value Health. 2001;4(3):225-250.
5. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
6. Medicare program: procedures for making national coverage decisions, 64 Federal Register 22619-22625 (1999).
7. Tengs TO, Meyer G, Siegel JE, et al. Oregon's Medicaid rankings and cost-effectiveness: is there any relationship? Med Decis Making. 1996;16:99-107.
8. Luce BR, Lyles AC, Rentz AM. The view from managed care pharmacy. Health Affairs. 1996;4:168-176.
9. Titlow K, Randel L, Clancy CM, Emanuel EJ. Drug coverage decisions: the role of dollars and values. Health Affairs. 2000;19(2):240-247.
10. Wallace JF, Weingarten SR, Chiou CF, et al. The limited incorporation of economic analyses in clinical practice guidelines. J Gen Intern Med. 2002;17:210-220.
11. Jacobson PD, Kanna ML. Cost-effectiveness analysis in the courts: recent trends and future prospects. J of Health Polit Policy Law. 2001;26(2):291-326.
12. Tengs TO, Graham JD. The opportunity costs of haphazard social investments in life-saving. In: Hahn RW, ed. Risks, Costs, and Lives Saved: Getting Better Results from Regulaton. New York, NY: Oxford University Press; 1996:167-182.
13. Eddy DM. Clinical decision making: from theory to practice. Cost-effectiveness analysis. A conversation with my father. JAMA. 1992;267:1669-1675.
14. Ubel PA. Pricing Life: Why it's Time for Health Care Rationing. Cambridge, Mass: MIT Press; 2000.
15. Udvarhelyi IS, Colditz GA, Rai A, Epstein AM. Cost-effectiveness and cost-benefit analyses in the medical literature: are they being used correctly? Ann Intern Med. 1992;116:238-244.
16. Evans R. Manufacturing consensus, marketing truth: guidelines for economic evaluation. Ann Intern Med. 1995;123:59-60.
17. Rennie D, Luft HS. Pharmacoeconomic analyses: making them transparent, making them credible. JAMA. 2000;283:2158-2160.
18. Prosser LA, Koplan JP, Neumann PJ, Weinstein MC. Barriers to using cost-effectiveness analysis in managed care decision making. Am J Manag Care. 2000;6:173-179.
19. Berger ML. The once and future application of cost-effectiveness analysis. J Qual Improve. 1999;25(9):455-461.
20. Langley PC. Is cost-effectiveness modeling useful? Am J Manag Care. 2000;6(2):250-251.
21. Asch DA, Jepson C, Hershey JC, Baron J, Ubel PA. When money is saved by reducing health care costs, where do US physicians think the money goes? Am J Manag Care. 2003;9(6):438-442.
22. Daniels N, Sabin JE. Setting Limits Fairly: Can We Learn to Share Medical Resources? New York, NY: Oxford University Press; 2002.
23. Ubel PA, Loewenstein G, Scanlon D, Kamlet M. Value measurement in cost-utility analysis: explaining the discrepancy between analog scale and person trade-off elicitations. Health Policy. 1998a:43:33-44.
24. Ubel PA, Spranca M, DeKay M, et al. Public preferences for prevention versus cure: what if an ounce of prevention is worth only an ounce of cure? Med Decis Making. 1998;18:141-148.
25. Perneger TV, Martin DP, Bovier PA. Physicians' attitudes towards health care rationing. Med Decis Making. 2002;22:65-70.
26. Hadorn DC. Setting health care priorities in Oregon: cost-effectiveness meets the rule of rescue. JAMA. 1991;265:2218-2225.
27. Hadorn DC. The problem of discrimination in health care priority setting. JAMA. 1992;268:1454-1459.
28. Heinzerling L, Ackerman F. Pricing the Priceless: Cost-benefit Analysis of Environmental Protection. Washington, DC: Georgetown Environmental Law and Policy Institute; 2002.
29. Kim M, Blendon RJ, Benson JM. How interested are Americans in new medical technologies? a multicountry comparison. Health Affairs. 2001;5:194-201.
30. Russell LB. Is Prevention Better Than Cure? Washington, DC: Brookings Institute; 1986.
31. Weinstein MC. High-priced technology can be good value for money. Ann Intern Med. 1999;130(10):857-858.
32. Neumann PJ. Evidence-based and value-based formulary guidelines. Health Affairs. 2004;23(1):124-134.
33. Goldman L, Weinstein MC, Goldman PA, et al. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA. 1991;265:1145-1151.
34. National Cholesterol Education Program (NCEP). The second report of the Expert Panel on Dectection, Evaluation, and Treatment. Circulation. 1994;89:1329-1495.
35. Saha S, Hoerger TI, Pignone MP, et al. The art and science of incorporating cost effectiveness into evidence-based recommendatio6s for clinical preventive services. Am J Prev Med. 2001;20(3S):36-43.
36. Carande-Kules VG, Maciosek MV, Briss PA, et al. Methods for systematic reviews of economic evaluations for the Guide to Community Preventive Services. Am J Prev Med. 2000;18(15):75-91.
37. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practice. N Engl J Med. 1977;296:716-721.
38. Sculpher M, Drummond M, O'Brien B. Effectiveness, efficiency, and NICE [editorial]. BMJ. 2001;322:943-944.
39. Mitchell AS. Antipodean assessment: activities, actions, and achievements. Int J Technol Assess in Health Care. 2002;18(2):203-212.
40. Weinstein MC. Should physicians be gatekeepers of medical resources? Journal Med Ethics. 2001;27:268-274.
41. Robinson JC. The end of managed care. JAMA. 2001;285:2622-2628.
42. Jefferson T, Demicheli V. Quality of economic evaluations in health care. BMJ. 2002;324:313-314.
43. Power EJ, Eisenberg JM. Are we ready to use cost-effectiveness analysis in health decision making? Med Care. 1998;36:MS10-MS17.
44. Neumann PJ. Medicare, cost-effectiveness, and new medical technology. Harvard Health Pol. Rev. In press.
45. Vladeck BC. Commentary on the Oregon Health Plan. Med Care Res Rev. 2000;57:235-242.
46. George B, Harris A, Mitchell A. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). PharmacoEconomics. 2001;19(11):1103-1109.
47. Taylor D. Funding medicines for people with multiple sclerosis. BMJ. 2001; 323:1379-1380.
48. Towse A, Pritchard C. Does NICE have a threshold? An external view. In: Towse A, Pritchard C, Devlin N, eds. Cost-Effectiveness Thresholds: Economic and Ethical Issues. London: Office of Health Economics;2002:25-30.